Top 16 Drugs in Rheumatology 2016 Save

Jack Cush, MD

Oct 24, 2017 3:00 am

Using data compiled from annual reports, SEC filings, press releases, company websites, recently released sales figures show that in 2016, 11 of the top 16 rheumatology drugs demonstrated blockbuster sales (>$1 billion per annum). Highlights from this report include:

TNF inhibitors – the big three TNFi (ADA, ETN, INF) lead the way with $33.7 billion in 2016. Humira continued as the worldwide leader in sales $16.1 billion. Sales of all 5 TNFi totaled $37.9 billion. While Humira growth (15%) continues, Enbrel has flattened (2%) and Remicade has declined (-2%).
Greatest growth from 2015 to 2016 was Cosentyx (332% to $1.1 billion in 2016), Otezla (116% to $1 billion) and Xeljanz (77% to $927 million).
Greatest losses were seen for NSAID market, with -12% drop for Celebrex, -4% drop for Arcoxia (Cox-2 inhibitor sold outside the USA) and a -2% drop for aspirin.
Psoriatic arthritis therapeutic market was hot with substantial growth by Cosentyx (332%), Otezla (116%) and Stelara (31%), in addition to TNF inhibitor growth.

TOP 16 RHEUMATOLOGY DRUGS – 2016 SALES

	Brand	Generic	2015 Sales*	2016 Sales*	Growth Rate
1	Humira	Adalimumab	14012	16078	15%
2	Enbrel	Etanercept	8697	8874	2%
3	Remicade	Infliximab	8791	8789	-2%
4	Rituxan	Rituximab	5584	5765	3%
5	Stelara	Ustekinumab	2474	3232	31%
6	Simponi	Golimumab	2133	2719	27%
7	Orencia	Abatacept	1957	.2368	21%
8	Actemra	Tocilizumab	1432	1697	19%
9	Cimzia	Certolizumab	1191	1438	21%
10	Cosentyx	Secukinumab	261	1128	332%
11	Otezla	Apremilast	472	1017	116%
12	Xeljanz	Tofacitinib	523	927	77%
13	Celebrex	Celcoxib	830	733	-12%
14	Aspirin	Aspirin	525	513	-2%
15	Arcoxia	Etoricoxib	471	450	-4%
16	Ilaris	Canakinumab	236	283	20%
* Worldwide sales expressed millions (USD)